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Abstract
Background and Aims: To investigate the efficacy and safety of three different dosages of 
embryonated, viable eggs of Trichuris suis [TSO] versus placebo for induction of remission in 
mildly-to-moderately active ileocolonic, uncomplicated Crohn’s disease [CD].
Methods: Adults with active CD [n = 252] randomly received six fortnightly doses of 250, 2500, or 
7500 TSO/15 ml suspension/day [TSO 250, TSO 2500, TSO 7500], or 15 ml placebo solution/day, in a 
double-blind fashion, with 4 weeks’ follow-up. Primary endpoint was the rate of clinical remission 
[Crohn’s Disease Activity Index [CDAI] < 150] at end of treatment, ie at Week 12 or withdrawal. 
Secondary endpoints included the course of clinical remission, rate of clinical response, change in 
CDAI, change in markers of inflammation, mucosal healing, and Physician’s Global Assessment.
Results: Clinical remission at Week 12 occurred in 38.5%, 35.2%, and 47.2% of TSO 250, TSO 2500, 
and TSO 7500 patients, respectively, and in 42.9% of placebo recipients. TSO induced a dose-
dependent immunological response. There was no response regarding laboratory markers of 
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inflammation. Other secondary efficacy variables also showed no advantage of TSO over placebo 
for treatment of active CD. Administration of TSO did not result in any serious adverse drug 
reaction. Review of non-serious suspected adverse drug reactions following TSO did not reveal 
any safety concerns.
Conclusions: Administration of 250–7500 TSO fortnightly over 12 weeks was safe and showed 
a dose-dependent immunological response, but no TSO dose showed a clinically relevant effect 
over placebo for induction of clinical remission or response in mildly-to-moderately active, 
ileocolonic CD.
Key Words:  Crohn’s disease; randomized; Trichuris suis ova [TSO]
1. Introduction
Despite significant improvements in understanding genetic sus-
ceptibility, pathways of inflammation, and the biology of inflam-
matory bowel disease [IBD], treatment is still unsatisfactory. Most 
approaches target pro-inflammatory signals and pathways, and 
include broad anti-inflammatory drugs such as 5-aminosalicylic acid 
or steroids, more specific immunosuppressants such as thiopurines, 
and antibodies to tumour necrosis factor or to integrins. Many other 
attempts to target components of the immune system have failed.1,2
Some, but not all, epidemiological data 3–6 suggest that the absence 
of some ‘old friends’, including helminths and other microbiota, and 
intensified hygiene during the first years of life, lead to increased mani-
festation of immune-related diseases such as IBD. 7–10 In particular, the 
association between an absence of helminth infections and the increased 
occurrence of immune-related disorders has led to many experimental 
studies.11,12 In animal models, helminths modulate the microbiota,13 
ameliorate dextran sodium sulphate-induced colitis,14 exert a protec-
tive effect on IL-10-mediated dinitrobenzene sulphonic acid-induced 
colitis,15 and improve IL-10 knockout colitis.16 They induce IL-I0 pro-
duction in lamina propria dendritic cells while decreasing IL-12p40,17 
and filarial cystatin induces IL-I0-producing macrophages.18 More 
recently, it has been found that products of Trichuris suis reduce the 
barrier function and suppress inflammatory cytokine production in 
intestinal epithelial cells.19 Based on these data, it has been suggested 
that helminths may influence immunoregulatory systems.
Accordingly, a number of clinical studies have been performed. 
In particular, a detailed case report of remission induction in severe 
ulcerative colitis by Trichuris trichiuria has received attention.20 
Currently, more than 20 clinical trials of helminth therapy have been 
planned, started, or completed. 21 A decade ago, Summers et al. pio-
neered clinical studies in IBD using non-pathogenic, embryonated, 
viable eggs [ova] of Trichuris suis [TSO].22,23 In a placebo-controlled 
trial in ulcerative colitis, improvement was significantly better in 
the TSO treatment arm,23 and an open-label study of patients with 
Crohn’s disease [CD] showed a 79% clinical response to TSO with 
clinical remission in 72% of patients.22 More recently, the safety and 
tolerability of TSO have been described in a randomised clinical 
trial, but efficacy data were not reported.24
Therefore, a prospective, randomised, double-blind, placebo-
controlled, multicentre trial comparing the efficacy and safety of 
fortnightly administration of 250, 2500, and 7500 TSO/15 ml sus-
pension/day versus placebo for induction of remission in mildly-to-
moderately active ileocolonic, uncomplicated CD was undertaken. 
The aim of the study was to confirm the preliminary efficacy results 
observed in the uncontrolled study22 and to demonstrate that TSO 
is superior to placebo for induction of clinical remission in CD by 
Week 12.
2. Methods
2.1. Study design and setting
This was a randomised, double-blind, placebo-controlled, multicen-
tre Phase II study undertaken to evaluate the efficacy and safety of 
three different dosages of TSO versus placebo in mildly-to-moder-
ately active CD patients. The study was performed during November 
2010 to February 2014 at 53 hospitals or private practices in Austria 
[n = 1], Czech Republic [n = 5], Denmark [n = 2], Germany [n = 43], 
and Switzerland [n = 2] [ClinicalTrials.gov number, NCT01279577; 
EudraCT number, 2006-000720-13]. The study was conducted in 
accordance with the International Conference on Harmonisation 
[ICH] Guideline for Good Clinical Practice and was approved by 
independent ethics committees for each centre. 
The study comprised a 7–10-day screening phase, a 12-week 
double-blind treatment phase with eight visits: Weeks 0 [baseline], 
1, 2, 4, 6, 8, 10, and 12 (end of treatment/withdrawal [EoT]), and a 
follow-up visit, which took place 4 weeks after the EoT visit.
The study was conducted with four treatment groups in the form 
of a parallel group comparison. The primary objective was to dem-
onstrate the superiority of any of the three TSO dosing groups com-
pared with placebo for the induction of clinical remission in CD.
2.2. Study population
For this Phase II trial, we included male and female patients between 
18 and 75 years of age with a confirmed diagnosis of mildly-to-mod-
erately active uncomplicated CD [Crohn’s disease activity index25,26 
[CDAI] ≥ 220 and ≤ 350], localised either in the terminal ileum 
[L1], the colon [L2], or ileocolon [L3]. Patients had to have elevated 
markers for inflammation at baseline (C-reactive protein [CRP] ≥ 2 x 
upper limit of normal [ULN; 5 mg/l] or stool calprotectin > ULN [50 
µg/g stool]) and could not be receiving any CD-specific concomitant 
treatment [except stable mesalazine].
Patients were not eligible for the study if any of the following 
major exclusion criteria was present: known Crohn’s lesions in the 
upper gastrointestinal tract [up to and including the jejunum] with 
present symptoms; evidence of infectious diarrhoea, abscess, per-
foration, active fistulas, or active perianal lesions; clinical signs of 
stricturing disease; treatment with immunosuppressants or biologics 
(anti-tumour necrosis factor [TNF]-α agents), anti-integrin agents, 
thiopurine [ie, azathioprine, 6-mercaptopurine, or 6-thioguanine], 
methotrexate, tacrolimus, cyclophosphamide, or cyclosporine] 
within the past 3 months prior to baseline; treatment with antibiot-
ics [eg, metronidazole or ciprofloxacin]; anti-parasitic medications 
within the past 2 weeks prior to baseline; or treatment with topi-
cal or systemic glucocorticosteroid within the past 4 weeks prior to 
baseline, or within the past 8 weeks if patients had been treated for 
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longer than 3 months. In addition, patients known to be steroid-
dependent or refractory, and patients who had been unresponsive 
both to treatment with a biologic [eg, anti-TNF-α agents or anti-
integrin agents] and a thiopurine were to be excluded.
2.3. Randomisation and study medication
2.3.1. Allocation to treatment
At baseline, eligible patients were allocated to treatment by a com-
puter-generated list of random numbers, using randomly permuted 
blocks with a flexible block size of 4 or 8. The list was generated 
and held by staff at a contract research organisation who were not 
involved in the planning, conduct, or analysis of the study. Patients 
were centrally randomised without any stratification in a 1:1:1:1 
ratio via an interactive web response system to receive double-
blind treatment with six fortnightly dosages of 250, 2500, or 7500 
TSO/15  ml suspension/day [TSO 250, TSO 2500, TSO  7500], or 
15 ml placebo solution.
2.3.2. Study medication
All trial medications were marked with an individual treatment 
kit number on each bottle. At Weeks 0, 2, 4, 6, 8, and 10 the 
treatment kit number of the bottle of the TSO/placebo suspension 
for one patient was provided to the investigator via the interac-
tive web response system. The content of the corresponding bot-
tle was gently shaken and administered by the patient directly at 
the study site under supervision of the study personnel, so that 
100% single dose compliance could be guaranteed. Each bottle 
contained 15 ml suspension of 250, 2500, or 7500 embryonated, 
viable TSO as the active ingredient, or a placebo solution, manu-
factured by Ovamed GmbH, Barsbüttel, Germany under good 
manufacturing practice conditions. The appearance and taste of 
the placebo solution were indistinguishable from those of the 
TSO suspension.
2.4. Evaluation schedule and assessments
At baseline and all subsequent visits, the CDAI [based on daily diary 
cards] for the visit was calculated, vital signs and patient’s quality of 
life (using the Short Health Scale [SHS]27) were recorded, and cen-
tral laboratory assessments were performed (stool samples analysed 
only at baseline and Weeks 4, 8, 12 [EoT visit] and follow-up visit). 
Physician’s Global Assessment [PGA] according to Hanauer et al.28 
was performed at the EoT visit.
Optionally, ileocolonoscopy was undertaken at baseline and EoT 
visit, in which case the Simple Endoscopic Score for Crohn’s Disease 
[SES-CD]29 was to be used to rate any endoscopic finding.
Since helminths can induce eosinophilia, the results of blood 
eosinophil counts and eosinophil derived neutoxin [EDN] levels in 
stools were kept blinded to the investigators during the study.
To evaluate a potential immunological effect of TSO adminis-
tration, the presence of T.  suis-specific excretory/secretory [E/S] 
antigen-specific antibodies was measured by an enzyme-linked 
immunosorbent assay [ELISA; total IgG]. The ELISA method, origi-
nally developed for pig serum,30 was adapted and validated for 
human serum by Parasite Technologies A/S, Horsholm, Denmark 
[validation data on file]. Serum samples obtained in a subset of 
patients [ie, six remitters and six non-remitters in each of the four 
treatment groups; a total of 48 patients] were analysed in order to 
confirm that the embryonated eggs of T. suis were viable and had 
hatched, by determining whether a TSO-specific immunological 
response had been induced.
2.5. Study endpoints
The primary efficacy endpoint was the proportion of patients achiev-
ing clinical remission, defined as a CDAI < 150 at EoT, ie at Week 
12 or withdrawal visit (last observation carried forward [LOCF]). 
The main secondary efficacy endpoints included the proportion of 
patients with clinical remission [CDAI < 150] in the course of the 
study, the proportion of patients with a reduction of ≥ 100 points in 
total CDAI at EoT compared with baseline, the mean change from 
baseline to EoT in total CDAI score, ‘treatment success’ and ‘treat-
ment benefit’ based on the PGA score at EoT,28 the mean change 
from baseline to EoT in CRP, stool calprotectin and stool lactoferrin, 
and the mean change from baseline to EoT in the four dimensions 
of the SHS. The proportion of patients with mucosal healing at EoT, 
with mucosal healing defined as a SES-CD 1 subscore of ‘0’, was 
calculated only for patients who had a baseline SES-CD 1 subscore 
of ‘≥ 1’.
Immunological endpoints were values for blood eosinophil 
counts and stool EDN and change from baseline [for each visit], 
and the optional E/S antigen ELISA [total IgG] results, which were 
obtained in a subset of patients showing the highest and lowest 
improvement in CDAI, respectively, and presented for each visit and 
standardised as percentage change from baseline.
Safety endpoints included vital signs and adverse events [clinical 
and laboratory] and laboratory test results [including faeces analy-
sis]. At the EoT visit, tolerability was independently assessed by the 
patient and the physician as very good, good, satisfactory, or poor.
2.6. Statistics
The study was performed using a two-stage group sequential adap-
tive design with possible sample size adjustment and optional stop-
ping of one or two of the active treatment arms after a prospectively 
planned interim analysis, conducted by an independent data moni-
toring committee [IDMC].
Assuming rates of clinical remission of 50% in any of the TSO 
groups and 20% in the placebo group at EoT, a sample size of 
53 patients in each group in the intention-to-treat [ITT] analysis 
[120 patients up to the interim analysis, 92 patients subsequently] 
would confer 80% power to yield a statistically significant result 
[one-sided α = 0.008] [see Supplementary Appendix 2, available as 
Supplementary data at ECCO-JCC online].
Evaluation of the primary efficacy variable was performed for the 
full analysis set [ITT analysis] and for the per-protocol [PP] set [PP 
analysis]. The primary analysis for confirmatory testing was the ITT 
analysis. For confirmatory hypothesis testing at the interim analysis 
as well as the final analysis, the inverse normal method of combining 
the p-values of the normal approximation tests for the comparison 
of rates was used [Supplementary Appendix 2]. If a patient discon-
tinued the study prematurely, the last CDAI value recorded under 
study medication was included [LOCF method]. Patients without 
a post-baseline CDAI value were regarded as not having shown a 
response to treatment. All p-values resulting from further statisti-
cal tests, as well as for analyses of secondary efficacy or safety end-
points, were interpreted in the exploratory sense and therefore, no 
correction of p-values for multiplicity was performed.
Statistical testing of the primary endpoint was done using the 
ADDPLAN 5 MC software [licensed by Addplan GmbH, an ICON 
company, Cologne, Germany]. All other analyses were conducted 
using the SAS V.9.2 statistical package for Windows [SAS Institute, 
Cary, NC, USA].
The safety and ITT population comprised all randomised 
patients who received at least one dose of study medication. The PP 
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population included all ITT patients without major protocol viola-
tions who were adequately compliant to study medication intake 
and study procedures, and provided at least one post-baseline CDAI 
value under study medication.
3. Results
3.1. Study population
In total, 430 patients were screened, of whom 254 met all eligibility 
criteria and were enrolled into the study. Of these, two patients were 
not randomised and did not receive any study treatment, and thus 
were excluded from the ITT analysis. A total of 252 patients were 
thus randomised and received study treatment and were included 
into the safety and ITT analysis sets; 184 completed the 12-week 
study visit [Figure 1]. In total, 86 ITT patients were excluded from 
the PP population, most frequently due to due to major protocol 
deviations [n = 62] [Figure 1].
Based on the results of the first interim analysis of 120 observed 
patients [30 patients in each group], the IDMC recommended a 
further interim analysis after recruitment of 240–250 patients. In a 
blinded manner, the IDMC also recommended discontinuation of the 
TSO 250 dosing group due to futility, as assessed by an unblinded stat-
istician via the central randomisation list, such that the investigators 
and the operational study team of the sponsor remained blinded. At 
the time of the IDMC’s recommendation, 156 patients were already 
enrolled. Therefore, stage 1 of the study includes all four treatment 
groups and consisted of 156 patients. At the second interim analysis, 
conducted after 239 patients had completed the study, the IDMC rec-
ommended the termination of further study recruitment due to futil-
ity. Since recruitment continued during the interim analysis, a total of 
252 patients were evaluable for the final ITT analysis set, of whom 96 
patients were analysed in stage 2 of the study.
The baseline demographic and clinical characteristics of the 
ITT population were similar between treatment groups [Table  1].
Objective parameters for inflammation confirmed the presence of 
inflammation in the patient population.
3.2. Clinical efficacy
3.2.1. Primary efficacy endpoint
A summary of clinical remission rates at Week 12 [LOCF] in the final 
analysis [ITT] is presented in Figure 2. Significant superiority over 
placebo was not observed in any of the TSO treatment groups. This 
finding was confirmed in a robustness analysis performed in the PP 
population [Supplementary Table 1, available as Supplementary data 
at ECCO-JCC online].
In several pre-planned subgroup analyses of the primary end-
point, the proportions of patients with clinical remission at EoT 
showed a large variability between treatment groups and between 
subgroups. No consistent difference in the proportions of patients 
with clinical remission at EoT between TSO and placebo treatment 
was detected in any subgroup [Supplementary Table 2, available as 
Supplementary data at ECCO-JCC online].
In a post hoc analysis, baseline characteristics of remitters versus 
non-remitters were evaluated in order to find any reason which could 
explain the observed high placebo response [Supplementary Table 3, 
available as Supplementary data at ECCO-JCC online]. However, 
no obvious difference or explanation was observed. Interestingly, the 
clinical remission rates were not consistent between the two stages of 
the study [Supplementary Table 4, available as Supplementary data 
at ECCO-JCC online].
Screened n=430
Not meeting in-/exclusion criteria n=176
Enrolled but not randomised n=2
Randomised & treated n=252
TSO 2500 fortnightly n=71 TSO 7500 fortnightly n=72
Safety/ITT n=72 Safety/ITT n=70Safety/ITT n=71Safety/ITT n=39
Discontinued n=12 
  7 lack of efcacy
  2 lack of cooperation 
  2 intolerable AE
  1 other reasons
Completed n=27
Major violations n=16
PP n=23* PP n=51* PP n=47* PP n=45*
Major violations n=20 Major violations n=25 Major violations n=25
Completed n=51 Completed n=55 Completed n=51
Discontinued n=20 
  16 lack of efcacy 
  3 lack of cooperation 
  1 intolerable AE 
  0 other reasons
Discontinued n=17 
  10 lack of efcacy 
  6 lack of cooperation 
  1 intolerable AE 
  0 other reasons
Discontinued n=19 
  16 lack of efcacy
  1 lack of cooperation 
  1 intolerable AE
  1 other reasons
Placebo fortnightly n=70TSO 250 fortnightly n=39
Enrolled n=254
Figure 1. Patient disposition. AE, adverse event; ITT, intention-to-treat; PP, per protocol; TSO, embryonated, viable eggs [ova] of Trichuris suis. * 86 ITT patients 
were excluded from the PP population (62 protocol deviations, 22 received <3 doses of study medication,18 discontinued the study prematurely, 6 end of 
treatment/withdrawal visit >21 days after last study drug administration [≥1 reason was possible]).
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Table 1. Baseline demographics and clinical characteristics [ITT]
n [%] /  
mean [SD]
TSO 250
[n = 39]
TSO 2500
[n = 71]
TSO 7500
[n = 72]
Placebo
[n = 70]
All
[n = 252]
Sex
 Male 19 [48.7%] 29 [40.8%] 24 [33.3%] 26 [37.1%] 98 [38.9%]
 Female 20 [51.3%] 42 [59.2%] 48 [66.7%] 44 [62.9%] 154 [61.1%]
Race
 White 39 [100.0%] 70 [98.6%] 70 [97.2%] 70 [100.0%] 249 [98.8%]
Age [years] 37.8 [9.5] 37.8 [11.0] 34.8 [11.0] 37.7 [12.8] 36.9 [11.3]
BMI [kg/m2] 23.1 [4.2] 24.5 [4.6] 24.9 [5.9] 24.2 [4.4] 24.3 [4.9]
Smoking habits
 Current 14 [35.9%] 20 [28.2%] 21 [29.2%] 18 [25.7%] 73 [29.0%]
 Former 10 [25.6%] 23 [32.4%] 18 [25.0%] 22 [31.4%] 73 [29.0%]
 Never 15 [38.5%] 28 [39.4%] 33 [45.8%] 30 [42.9%] 106 [42.1%]
Case history
 Established disease 29 [74.4%] 41 [57.7%] 51 [70.8%] 46 [65.7%] 167 [66.3%]
 Chronic course 8 [20.5%] 19 [26.8%] 18 [25.0%] 23 [32.9%] 68 [27.0%]
 New diagnosis 2 [5.1%] 11 [15.5%] 3 [4.2%] 1 [1.4%] 17 [6.7%]
Duration of disease since first  
diagnosis of CD [years]
8.0 [6.8] 7.9 [7.8] 6.4 [6.4] 9.5 [7.4] 7.9 [7.2]
Median [range] 5.9 [0.3–29.1] 5.6 [0.0–34.3] 4.1 [0.1–30.2] 7.2 [0.5–30.7] 5.9 [0.0–34.3]
 < 5 years 16 [41.0%] 33 [46.5%] 39 [54.2%] 24 [34.3%] 112 [44.4%]
 ≥ 5 years 23 [59.0%] 38 [53.5%] 33 [45.8%] 46 [65.7%] 140 [55.6%]
Localisation of disease
 Ileocoecala 18 [46.2%] 34 [47.9%] 38 [52.8%] 37 [52.9%] 127 [50.4%]
 Ileocolonicb 12 [30.8%] 16 [22.5%] 16 [22.2%] 14 [20.0%] 58 [23.0%]
 Colonicc 9 [23.1%] 13 [18.3%] 12 [16.7%] 12 [17.1%] 46 [18.3%]
Concomitant treatment
 Mesalazine 9 [23.1%] 16 [22.5%] 17 [23.6%] 12 [17.1%] 63 [23.8%]
Extraintestinal manifestations at 
baseline
 Arthralgia 15 [38.5%] 24 [33.8%] 18 [25.0%] 21 [30.0%] 78 [31.0%]
 Arthritis 8 [20.5%] 4 [5.6%] 10 [13.9%] 15 [21.4%] 37 [14.7%]
 Iritis 4 [10.3%] 3 [4.2%] 2 [2.8%] 4 [5.7%] 13 [5.2%]
 Erythema nodosum 2 [5.1%] 1 [1.4%] 1 [1.4%] 1 [1.4%] 5 [2.0%]
 Aphthous stomatitis 2 [5.1%] 2 [2.8%] 3 [4.2%] 3 [4.3%] 10 [4.0%]
 Uveitis 2 [5.1%] --- 1 [1.4%] 2 [2.9%] 5 [2.0%]
 Pyoderma gangrenosum 1 [2.6%] 2 [2.8%] --- 1 [1.4%] 4 [1.6%]
CDAI at baseline 267 [40.0] 266 [38.8] 271 [46.8] 271 [46.5] 269 [43.3]
Calprotectin at baseline [µg/g] 1073 [1473] 
n = 38
1614 [2115] 
n = 71
1452 [2226] 
n = 71
1146 [1846] 
n = 70
1355 [1991] 
n = 250
Median [range] 551 [77–6322] 892 [33–12 000] 557 [56–12 000] 503 [48–12 000] 592 [33–12 000]
 > ULN 38 [97.4%] 70 [98.6%] 71 [98.6%] 69 [98.6%] 248 [98.4%]
 > 5 x ULN 29 [74.4%] 58 [81.7%] 50 [69.4%] 49 [70.0%] 186 [73.8%]
CRP at baseline [mg/l] 15.3 [22.4] 18.0 [25.7] 20.4 [26.1] 18.9 [24.2] 18.5 [24.8]
Median [range] 6.9 [0.1–99.9] 8.8 [0.1–135.5] 12.8 [0.1–121.2] 10.8 [0.1–150.8] 10.6 [0.1–150.8]
 > ULN 22 [56.4%] 43 [60.6%] 48 [66.7%] 47 [67.1%] 160 [63.5%]
 > 2 x ULN 17 [43.6%] 32 [45.1%] 41 [56.9%] 38 [54.3%] 128 [50.8%]
Calprotectin > 5 x ULN and CRP > 
2 x ULN
9 [39.1%] 21 [41.2%] 19 [40.4%] 17 [37.8%] 66 [39.8%]
SES-CD at baseline 4.3 [0.6] n = 3 12.7 [7.0] n = 15 11.0 [6.1] n = 16 10.1 [7.4] n = 8 11.0 [6.6] n = 42
Median [range] 4 [4–5] 11 [4–24] 9.5 [3–20] 7.5 [3–20] 9 [3–24]
Previous treatment with azathioprine 3 [7.7] 5 [7.0] 4 [5.6] 7 [10.0] 19 [7.5]
Previous treatment with α-TNF 1 [2.6] 5 [7.0] 5 [6.9] 5 [7.1] 16 [6.3]
aInflammation only in terminal ileum, neoterminal ileum, and/or caecum.
bInflammation in terminal ileum, neoterminal ileum, and/or caecum and in at least one of the following segments: ascending colon, transverse colon, descend-
ing colon, sigmoid and/or rectum.
cInflammation only in at least one of the following segments: ascending colon, transverse colon, descending colon, sigmoid and/or rectum
BMI, body mass index; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; ITT, intention-to-treat; SD, standard devia-
tion; SES-CD, Simple Endoscopic Score for Crohn’s Disease; TNF, tumour necrosis factor; TSO, embryonated, viable eggs [ova] of Trichuris suis; ULN, upper 
limit of normal.
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Remission rates in both the placebo group and the TSO 2500 
group increased towards the end of the study [Supplementary 
Table 4].
3.2.2. Secondary efficacy endpoints
The course of clinical remission showed no clinically relevant or sta-
tistically significant difference between the active treatment groups 
compared with placebo [Figure 3]. In line with this, the major sec-
ondary efficacy endpoints also revealed no signs of clinically relevant 
or statistically significant difference between the TSO groups and 
placebo [Table 2].
Of note, despite a clinical response in all treatment groups, 
there was no clinically relevant change from baseline in markers for 
inflammation.
The four scores of the SHS questionnaire showed a mean 
decrease from baseline to EoT in all treatment groups, indicating an 
improvement in patients’ quality of life.
The total SES-CD could be calculated for only 42 patients at 
baseline and 37 patients at the EoT/withdrawal visit. Due to the 
low number of patients with evaluable values for total SES-CD, no 
descriptive analyses of total SES-CD and changes in total SES-CD 
were performed. The proportions of patients with mucosal healing 
at the EoT/withdrawal visit were calculated on the basis of SES-CD 
1. Mucosal healing was defined as change in SES-CD 1 from val-
ues ‘≥ 1’ at baseline to ‘0’ at the EoT/withdrawal visit in any loca-
tion. Two patients each in the TSO 250 and placebo groups, and 
one patient each in the TSO 2500 and TSO 7500 groups, showed 
mucosal healing at the EoT/withdrawal visit.
3.3. Immunological response
The course of the relative percentage change in blood eosinophil 
counts from baseline is presented in Figure 4a. A difference between 
the placebo and TSO groups was observed from Week 4 onwards, 
with a dose-dependent increase in the TSO treatment groups which 
peaked between Week 6 and Week 8 of treatment. The course of the 
absolute change from baseline in EDN levels in stools is depicted in 
Figure 4b. A similar pattern was observed, with a clear dose-depend-
ent response in the TSO groups.
Since the primary and major secondary endpoints were not met, 
a T. suis-specific humoral response was measured in only 12 patients 
per treatment group instead of in all patients as originally planned. Six 
patients in each group were selected who were in remission at EoT and 
showed the highest decrease in the total CDAI score from baseline, as 
well as six patients who were non-remitters at EoT and showed the 
lowest decrease or even an increase from baseline in the total CDAI 
score. Results of the analysis of T. suis E/S antigen-specific total IgG, 
expressed as ‘% of reference serum’ are displayed in Figure 4c as the 
relative overall change from baseline. A clear dose-dependent immu-
nological response was observed after three administrations [ie, after 
week 4] of TSO. Moreover, the immunological response was some-
what delayed in the TSO 2500 group compared with the TSO 7500 
group. Stratified analysis by remitter versus non-remitter showed that 
the non-remitters also showed a relevant immunological response 
only in the TSO 7500 group [Figure 4d]. In all other TSO groups, only 
the remitters showed a relevant immunological response.
3.4. Safety
The proportion of patients with treatment-emergent adverse events 
was similar in the treatment groups: 72% TSO 250, 72% TSO 2500, 
76% TSO 7500, 73% placebo [see Supplementary Table 5, available 
as Supplementary data at ECCO-JCC online, for details].
Suspect adverse drug reactions [ADRs, ie at least possibly related 
to study medication] were reported in 13%, 23%, 8%, and 19% of 
patients on TSO 250, TSO 2500, TSO 7500, and placebo, respec-
tively. ADRs following TSO administration were most often gas-
trointestinal disorders [Table  3]. A  detailed overview of ADRs is 
given in Supplementary Table 6, available as Supplementary data at 
ECCO-JCC online. There were 23 serious adverse events reported 
[TSO 250: 2, TSO 2500: 3, TSO 7500: 7, placebo: 11]. Apart from 
a hypersensitivity reaction following administration of placebo solu-
tion, no other serious adverse event was assessed by the investigator 
as at least possibly related to study medication.
Withdrawal due to an adverse event was recorded in 23%, 21%, 
18%, and 20% of patients in the TSO 250, TSO 2500, TSO 7500, 
and placebo groups, respectively. The majority of patients were 
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Figure 2. Clinical remission (Crohn’s disease activity index [CDAI] < 150) at 
Week 12 (last observation carried forward [LOCF]] in the intention-to-treat 
[ITT] population). CI, confidence interval; TSO, embryonated, viable eggs 
[ova] of Trichuris suis.
TSO Versus Placebo in Active Crohn’s Disease 395
Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/11/4/390/2333902/A-Randomised-Double-blind-Placebo-controlled-Trial
by Copenhagen University Library user
on 21 September 2017
Table 2. Major secondary efficacy endpoints [ITT].
TSO 250 [n = 39] TSO 2500 [n = 71] TSO 7500 [n = 72] Placebo [n = 70]
≥ 100 points drop in CDAI n [%] 16/39 [41.0%] 31/71 [43.7%] 36/72 [50.0%] 32/70 [45.7%]
Change in total CDAI Mean [SD]
95% CI
-67 [100.6]
[-99.9‚ -34.6]
-83 [111.6]
[-109.7‚ -56.8]
-102 [111.4]
[-127.7‚ -75.4]
-83 [127.0]
[-112.8‚ -52.2]
CRP [mg/l]
 Screening Mean [SD] 16.1 [20.5] n = 38 16.8 [20.5] n = 71 17.0 [21.6] n = 71 17.8 [21.7] n = 70
 Week 12 [LOCF] Mean [SD] 19.7 [30.0] n = 39 15.6 [24.1] n = 71 19.5 [25.6] n = 71 18.6 [23.9] n = 70
 Change Mean [SD] 3.9 [26.4] n = 39 -1.2 [15.7] n = 71 2.6 [23.8] n = 71 0.8 [18.8] n = 70
Calprotectin [µg/g]
 Screening Mean [SD] 1073 [1473.0] n = 38 1614 [2115.3] n = 71 1452 [2225.9] n = 71 1146 [1846.3] n = 70
 Week 12 [LOCF] Mean [SD] 1375 [2003.4] n = 39 1112 [1420.3] n = 68 1559 [2556.9] n = 69 952 [1086.6] n = 62
 Change Mean [SD] 325 [1907.8] n = 38 -465 [2401.0] n = 68 183 [2394.2] n = 68 26 [1352.6] n = 62
Lactoferrin [µg/ml]
 Screening Mean [SD] 124 [220.9] n = 36 147 [293.7] n = 71 136 [228.7] n = 72 141 [296.2] n = 70
 Week 12 [LOCF] Mean [SD] 134 [243.5] n = 39 105 [171.5] n = 68 167 [356.9] n = 69 100 [200.6] n = 62
 Change Mean [SD] 14 [294.9] n = 36 -34 [325.3] n = 68 37.4 [340.2] n = 69 -5 [250.4] n = 62
PGA Week 12 [LOCF]
 Treatment successa n [%] 9 [23.1%] 20 [28.2%] 19 [26.4%] 16 [22.9%]
 Treatment benefitb n [%] 22 [56.4%] 39 [54.9%] 43 [59.7%] 40 [57.1%]
Short Health Scales: change from  
baseline
 Symptom burden Mean [SD] -9.7 [27.6] n = 38 -14.1 [26.0] n = 71 -18.7 [29.1] n = 68 -15.1 [27.0] n = 70
 Social function Mean [SD] -11.1 [26.2] n = 38 -17.1 [28.4] n = 71 -20.0 [28.2] n = 68 -16.3 [31.6] n = 70
 Disease-related worry Mean [SD] -11.2 [26.6] n = 38 -15.2 [26.3] n = 71 -17.2 [28.0] n = 68 -17.7 [29.4] n = 70
 General well-being Mean [SD] -7.1 [29.5] n = 38 -8.0 [24.8] n = 71 -17.7 [26.5] n = 68 -14.8 [27.9] n = 70
aPatients with either complete relief of symptoms or marked improvement of symptoms.
bPatients with either complete relief of symptoms, or marked improvement of symptoms, or moderate improvement of symptoms, or slight improvement of 
symptoms.
CDAI, Crohn’s disease activity index; CI, confidence interval; CRP, C-reactive protein; ITT. Intention-to-treat; LOCF, last observation carried forward; PGA, 
Physician’s Global Assessment; SD, standard deviation; TSO, embryonated, viable eggs [ova] of Trichuris suis.
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withdrawn from the study due to lack of efficacy, but no patient was 
withdrawn due to an intolerable suspected ADR.
Laboratory results raised no safety concerns. As expected, TSO 
treatment resulted in a marked increase in eosinophils in the blood. 
In two patients in the TSO 7500 group, eggs of T. suis were detected 
microscopically in faeces once at Week 12, with a negative result at 
follow-up.
Despite use of contraception [oral contraceptive; diaphragm/con-
dom] two patients on TSO 7500 became pregnant during the course 
of the study, resulting in the birth of a healthy baby in one case and 
spontaneous abortion in the other. Abortion was not classified as an 
ADR by the supervising investigator.
Tolerability of TSO was assessed by both the investigators and 
patients as very good or good in the vast majority of patients.
4. Discussion
This is the first randomised, double-blind, placebo-controlled, mul-
ticentre Phase II proof-of-concept study to evaluate the efficacy and 
safety of three different dosages of TSO for induction of remission 
in mildly-to-moderately active, ileocolonic, uncomplicated CD. The 
trial failed to show superiority of TSO treatment versus placebo for 
the primary endpoint, induction of clinical remission at Week 12 
[LOCF] in patients with active CD. Nor did the secondary efficacy 
variables show any advantage of TSO over placebo for the treat-
ment of active CD. Safety results were favourable, similar to those 
described in previous study reports.24,31,32
The absence of a clinically relevant benefit for TSO treatment does 
not appear to have been due a lack of embryonated, viable T. suis eggs 
or hatched larvae. Administration of TSO led to a dose-dependent 
increase in the percentage of blood eosinophils and stool EDN levels, 
as would be expected in patients affected with T. suis. Additionally, a 
dose-dependent specific humoral immunological response to E/S anti-
gen of T. suis, with seroconversion to IgG, was recorded in a subgroup 
of patients in each treatment group. Thus, the pharmacodynamic assess-
ments and immunological tests clearly indicate that TSO administration 
exerted an effect on the host, but had no influence on rates of clinical 
remission. There are other possible reasons for this disappointing result. 
First, the duration of treatment has been insufficient considering the 
long-established disease in this cohort of patients [median 4–7 years]. 
Treatment for 6–12 months may be required to achieve a clinical effect. 
21 Second, induction of remission may be the wrong outcome measure. 
Maintenance of quiescent disease over a prolonged period could have 
been a better approach. Third, the hygiene hypothesis may be incor-
rect. The inverse relationship between the presence of helminths and 
the manifestation of immune-related disease may only be a marker for 
more general lifestyle changes. 21 The fact that some other trials of TSO 
in other indications also failed33 points in this direction. In the future, it 
might be worthwhile to use helminth products in an appropriate form 
systemically or locally in order to achieve a more pronounced effect 
and possibly reduce the placebo response.34,35 The very high placebo 
response in this study, in spite of the clear proof of ongoing inflamma-
tion at entry into the trial with no change in inflammatory parameters, 
points to a strong mental signal36 which may be associated with the idea 
of swallowing a ‘living drug’ such as helminth eggs.
A wide range of post hoc analyses did not reveal a reason for 
the high response rate in the placebo arm. Patients opting for this 
type of treatment may have been recruited by accepting the belief 
of physicians to a large extent. The increased remission rate in the 
second stage of the study in most groups may support this view.
The typical side effects of TSO are gastrointestinal disorders, 
probably due to attachment of larvae to the mucosal epithelium. In 
studies of other diseases, such as allergic rhinitis32 and multiple scle-
rosis,37 transient gastrointestinal adverse events occurred in approxi-
mately 50% of patients treated with TSO. This high frequency of 
adverse events was not apparent in this study, probably due to over-
lap with IBD-related symptoms.
Following high doses of TSO, very small numbers of ova might 
be detected in stools. This was a rare observation in our trial. In 
accordance with other authors, it was classified as a sign that eggs 
were being passed through rather than infection with new egg pro-
duction.37 Nevertheless, it is prudent to bear in mind the possibility 
of larval invasiveness,38 and careful safety monitoring is therefore 
mandatory in any patient receiving TSO.
In conclusion, this study provides no evidence for a positive effect 
of different doses of TSO over 12 weeks for the induction of remis-
sion in CD patients with proven active inflammatory disease. The 
application of TSO or placebo induced a relatively high subjective 
response, as measured by the CDAI and the PGA, but had no impact 
on objective parameters of inflammation such as CRP or calprotec-
tin, in spite of evidence for an immunological effect indicating arrival 
and hatching of T. suis larvae in the digestive tract.
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TSO, embryonated, viable eggs [ova] of Trichuris suis.
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